Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 2/20 | 0.66 |
| ▸ | PIK3CG | P48736 | 15/20 | 0.51 |
| ▸ | PIK3CA | P42336 | 10/20 | 0.51 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | CLK1 | P49759 | 1/20 | 0.42 |
| ▸ | CLK2 | P49760 | 1/20 | 0.42 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1304344 | 0.91 | PIK3CD (0.70) | PIK3CDPIK3CGPIK3CAABL1PIK3CB | |
| SCHEMBL1303667 | 0.88 | PIK3CD (0.65) | PIK3CDPIK3CGPIK3CAABL1PIK3CB | |
| SCHEMBL13189041 | 0.86 | PIK3CG (0.61) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL1302560 | 0.84 | PIK3CD (0.71) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL13188185 | 0.82 | PIK3CD (0.69) | PIK3CDPIK3CGPIK3CAABL1CSNK1D | |
| SCHEMBL1946984 | 0.80 | PIK3CD (1.00) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL3708631 | 0.80 | CLK1 (0.48) | PIK3CDPIK3CGPIK3CAABL1PIK3CB | |
| SCHEMBL13673276 | 0.80 | PIK3CD (0.78) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL1947780 | 0.80 | PIK3CD (0.72) | PIK3CDPIK3CGPIK3CAABL1 | |
| SCHEMBL1303433 | 0.79 | PIK3CD (0.41) | PIK3CDPIK3CGPIK3CAPIK3CBCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | claimed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | claimed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | claimed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | claimed |
| US-8053574-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-11-08 | — | — | US | disclosed |
| WO-2010100144-A1 | FUSED BICYCLIC COMPOUNDS AS INHIBITORS FOR PI3 KINASE | MERCK SERONO S.A. (CH) | 2010-09-10 | — | — | WO | disclosed |
| US-20100197682-A1 | Organic Compounds | NOVARTIS AG | 2010-08-05 | — | — | US | disclosed |
| EP-2178868-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | Novartis Ag (CH) | 2010-04-28 | — | — | EP | disclosed |
| WO-2009010530-A1 | BICYCLIC HETEROARYL COMPOUNDS AND THEIR USE AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2009-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197682-A1 | Organic Compounds | PIK3CA, PI4KA, PI4KB | PIK3CD 9/4885PIK3CG 11/4885PIK3CA 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.